Apellis制药 APLS 深 沪
交易中 03-27 10:32:01 美东时间
17.34
-0.320
-1.81%
华盛通- 最 高20.80
- 今 开17.55
- 成交量 6.01万股
- 最 低 16.835
- 昨 收 17.66
- 总市值 185.54万
- 52周最高 30.48
- 市盈率 静 --
- 换手率 56.16%
- 52周最低 16.10
- 委 比 13.54%
- 总股本 0.00亿
- 历史最高 94.75
- 量 比 0
- 振 幅 22.45%
- 历史最低 1.10
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Apellis Valuation Ignores Empaveli Potential, Says Analyst
BofA upgraded Apellis to Buy, citing strong early Empaveli uptake, FDA approval in rare kidney disease, and long-term sales upside.
01-22 02:14
Apellis Pharmaceuticals FY25 Preliminary U.S. Net Product Revenues Of $689M
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe planned in 1H
01-12 20:10
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.
2025-11-13 02:36
大摩上调Apellis Pharmaceuticals目标价至26美元 维持“持有”评级
摩根士丹利分析师Judah Frommer发表研报，将Apellis Pharmaceuticals(APLS.US)目标价从25美元上调至26美元，同时维持“持有”评级。Frommer表示，这一评级是基于该公司市场地位及近期财务战略所作出的判断。 分析师特别指出，Apellis与Sobi公司达成的重大特许权购买协议具有战略意义。该协议不仅确保Apellis可获得最高3亿美元收益(其中包含2.75亿美元首付款)，更将Sobi在Aspaveli销售中的特许权义务削减了90%。这一举措不仅为Apellis带来即时财务收益，甚至有望缓解投资者对其盈利能力的担忧。 尽管存在这些积极因素，Frommer...
2025-07-07 11:58
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
EMPAVELI在Phase 3 VALIANT研究中对C3G和IC-MPGN患者显示蛋白质尿显著减少、肾功能稳定，且未见新安全信号。FDA和EMA正在审查上市申请。
2025-06-06 13:15
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Apellis Pharmaceuticals will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025. The live webcast will be available on the company’s website, with a replay accessible for 90 days.
2025-06-04 11:00
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
AnaptysBio will host an investor call on June 3, 2025, at 4:15pm ET / 1:15pm PT to discuss updated Phase 2b RENOIR trial data for rosnilimab, with experts Paul Emery and Jonathan Graf. Live webcasts and replays will be available on its website. The company’s executives will also attend the Jefferies Global Healthcare Conference on June 5 and the Goldman Sachs Global Healthcare Conference on June 11.
2025-05-27 20:15
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a comple...
2024-09-23 20:12
What's Going With Apellis Pharmaceuticals Stock Friday?
Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following re-examination.
2024-09-20 22:45
Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals
Across the recent three months, 15 analysts have shared their insights on Apell...
2024-09-14 05:01
